These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19841624)

  • 1. Locking out viral replication.
    Begley DW; Varani G
    Nat Chem Biol; 2009 Nov; 5(11):782-3. PubMed ID: 19841624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication of the hepatitis C virus in cell culture.
    Bartenschlager R; Kaul A; Sparacio S
    Antiviral Res; 2003 Oct; 60(2):91-102. PubMed ID: 14638404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of hepatitis C virus inhibitors.
    Smith RM; Wu GY
    J Viral Hepat; 2003 Nov; 10(6):405-12. PubMed ID: 14633172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA.
    Parsons J; Castaldi MP; Dutta S; Dibrov SM; Wyles DL; Hermann T
    Nat Chem Biol; 2009 Nov; 5(11):823-5. PubMed ID: 19767736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment of cell lines expressing HCV replicon and its applications].
    Sakamoto N; Enomoto N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):116-20. PubMed ID: 15359775
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.
    Dahari H; Perelson AS
    World J Gastroenterol; 2007 Jun; 13(21):3020-1. PubMed ID: 17589958
    [No Abstract]   [Full Text] [Related]  

  • 8. Unravelling hepatitis C virus replication from genome to function.
    Lindenbach BD; Rice CM
    Nature; 2005 Aug; 436(7053):933-8. PubMed ID: 16107832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the replication of a hepatitis C virus-like RNA template by interferon and 3'-deoxycytidine.
    King RW; Zecher M; Jefferies MW
    Antivir Chem Chemother; 2002 Nov; 13(6):363-70. PubMed ID: 12718408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.
    Ye J; Wang C; Sumpter R; Brown MS; Goldstein JL; Gale M
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15865-70. PubMed ID: 14668447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of influenza virus biopolymers functions and reproduction of the virus by oligodeoxynucleotide derivatives.
    Yurchenko LV; Abramova TV; Ivanova EM; Nevinsky GA; Nomokonova NY; Fokina TN; Vlassov VV
    Nucleic Acids Symp Ser; 1991; (24):301. PubMed ID: 1841358
    [No Abstract]   [Full Text] [Related]  

  • 12. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of subgenomic hepatitis C virus replication by 5'-O-masked analogues of 6-chloropurine-2'-deoxyriboside.
    Ikejiri M; Ohshima T; Kato K; Toyama M; Murata T; Shimotohno K; Maruyama T
    Nucleic Acids Symp Ser (Oxf); 2007; (51):439-40. PubMed ID: 18029775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.
    Contreras AM; Hiasa Y; He W; Terella A; Schmidt EV; Chung RT
    J Virol; 2002 Sep; 76(17):8505-17. PubMed ID: 12163570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication.
    Roy S; Gupta N; Subramanian N; Mondal T; Banerjea AC; Das S
    J Gen Virol; 2008 Jul; 89(Pt 7):1579-1586. PubMed ID: 18559927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV.
    Meissner EG
    Liver Int; 2015 Feb; 35(2):295-6. PubMed ID: 25424883
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular mechanisms of hepatitis C virus (HCV) replication - implications for the development of antiviral drugs].
    Bühler S; Bartenschlager R
    Z Gastroenterol; 2011 Jul; 49(7):836-44. PubMed ID: 21766263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus replication cycle.
    Bartenschlager R; Cosset FL; Lohmann V
    J Hepatol; 2010 Sep; 53(3):583-5. PubMed ID: 20579761
    [No Abstract]   [Full Text] [Related]  

  • 19. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.
    Shahidi M; Tay ESE; Read SA; Ramezani-Moghadam M; Chayama K; George J; Douglas MW
    J Gen Virol; 2014 Nov; 95(Pt 11):2468-2479. PubMed ID: 25053565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.
    Mandour M; Vliegen I; Paeshuyse J; Neyts J
    Antiviral Res; 2018 Jan; 149():150-153. PubMed ID: 29154807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.